These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15684199)

  • 21. Celecoxib, rofecoxib, and acute temporary visual impairment.
    Coulter DM; Clark DW; Savage RL
    BMJ; 2003 Nov; 327(7425):1214-5. PubMed ID: 14630760
    [No Abstract]   [Full Text] [Related]  

  • 22. COX-2 inhibitors still eyed for cancer prevention.
    Thompson CA
    Am J Health Syst Pharm; 2005 May; 62(9):890, 894. PubMed ID: 15851492
    [No Abstract]   [Full Text] [Related]  

  • 23. [COX-2 inhibitors--one step forward and two steps back].
    Evensen S; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.
    Weaver A; Alderman M; Sperling R
    Am J Cardiol; 2003 May; 91(10):1291-2. PubMed ID: 12745131
    [No Abstract]   [Full Text] [Related]  

  • 25. A side effect of COX-2 inhibitors.
    Harv Health Lett; 2003 Apr; 28(6):7. PubMed ID: 12777233
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.
    Mamdani M; Rochon P; Juurlink DN; Anderson GM; Kopp A; Naglie G; Austin PC; Laupacis A
    Arch Intern Med; 2003 Feb; 163(4):481-6. PubMed ID: 12588209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease?
    Messerli FH; Sichrovsky T
    Am J Cardiol; 2005 Sep; 96(6):872-3. PubMed ID: 16169380
    [No Abstract]   [Full Text] [Related]  

  • 28. Tailoring arthritis therapy in the wake of the NSAID crisis.
    Olsen NJ
    N Engl J Med; 2005 Jun; 352(25):2578-80. PubMed ID: 15972863
    [No Abstract]   [Full Text] [Related]  

  • 29. Balancing the risks and benefits of celecoxib.
    Caldwell B; Beasley R; Weatherall M; Metcalfe S
    Am J Med; 2007 Jun; 120(6):e17. PubMed ID: 17524734
    [No Abstract]   [Full Text] [Related]  

  • 30. A tale of two coxibs.
    Hegmann T
    JAAPA; 2005 Mar; 18(3):14, 17. PubMed ID: 15789666
    [No Abstract]   [Full Text] [Related]  

  • 31. Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk.
    Lee YH; Ji JD; Song GG
    Rheumatol Int; 2007 Mar; 27(5):477-82. PubMed ID: 17051359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
    Meyer CH
    Klin Monbl Augenheilkd; 2005 Jan; 222(1):62-3. PubMed ID: 15678404
    [No Abstract]   [Full Text] [Related]  

  • 33. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
    Andersohn F; Schade R; Suissa S; Garbe E
    Stroke; 2006 Jul; 37(7):1725-30. PubMed ID: 16728684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased risk of cardiovascular events with coxibs and NSAIDs.
    Emery P; Moore A; Hawkey C
    Lancet; 2005 Apr 30-May 6; 365(9470):1538. PubMed ID: 15866301
    [No Abstract]   [Full Text] [Related]  

  • 36. Pfizer: Celebrex increases heart attack risk.
    Health News; 2005 Feb; 11(2):2. PubMed ID: 15732142
    [No Abstract]   [Full Text] [Related]  

  • 37. Cyclooxygenase inhibition: between the devil and the deep blue sea.
    Hawkey CJ
    Gut; 2002 May; 50 Suppl 3(Suppl 3):III25-30. PubMed ID: 11953329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular risk associated with celecoxib.
    Brophy JM
    N Engl J Med; 2005 Jun; 352(25):2648-50; author reply 2648-50. PubMed ID: 15972876
    [No Abstract]   [Full Text] [Related]  

  • 39. Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.
    Harv Heart Lett; 2006 Oct; 17(2):1-3. PubMed ID: 17153752
    [No Abstract]   [Full Text] [Related]  

  • 40. Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs.
    Budenholzer BR
    BMJ; 2002 Jul; 325(7356):161; author reply 161. PubMed ID: 12130617
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.